Abstract Library

#4557 miR-1290 and miR-320c regulate cell proliferation and predict patient prognosis in neuroendocrine carcinomas

Introduction: The biology of neuroendocrine carcinomas (NECs) remains largely unknown, limiting the use of biomarkers for patient stratification and therapy response prediction in clinical practice.

Conference:

Presenting Author: Liverani C

Authors: Liverani C, Sgolacchia F, Bongiovanni A, Calabrese C, Vanni S,

Keywords: biomarker, miRNAs, neuroendocrine carcinoma,

#3865 Prospective observational study on third-line treatments in neuroendocrine carcinoma – Data from the phase II SENECA trial

Introduction: Neuroendocrine Carcinoma (NEC) are very rare and characterized by a poor prognosis. Therapeutic opportunities for metastatic disease beyond the first line are very limited.

Conference:

Presenting Author: Liverani C

Authors: Bongiovanni A, Liverani C, Morbini S, Pusceddu S, Gelso F,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, third line, chemotherapy,

#3647 Autologous ECM-composed scaffolds and zebrafish PDXs for individualized theragnostic in rare neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are a subgroup of poorly characterized rare tumors with challenging management. Identification of clinically useful biomarkers for treatment tailoring is urgently needed.

Conference:

Presenting Author: Liverani C

Authors: Calabrese C, Miserocchi G, Vanni S, Mercatali L, de Vita A,

Keywords: NGS, zebrafish, autologous scaffold, molecular determinants,

#3025 Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis

Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bongiovanni A, Liverani C, Recine f, Fausti V, Mercatali L,

Keywords: pazopanib, neuroendocrine neoplasia, neuroendocrine tumors, meta-analysis, carcinoid,

#3016 DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance

Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liverani C

Authors: Liverani C, Bongiovanni A, Pieri F, Foca F, Ravaioli S,

Keywords: DLL3, RB1, prognostic biomarker, GEP-NEN,